Chicago, IL (May 27, 2026) – Researchers and clinicians from the Mount Sinai Tisch Cancer Center will present new research at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place Friday, May 29, through Tuesday, June 2, at McCormick Place in Chicago.
Mount Sinai investigators will contribute to presentations across multiple cancer specialties, including hematologic malignancies, thoracic oncology, urothelial cancer, gynecologic oncology, translational science, and cancer care delivery.
“ASCO is one of the most important global forums for advancing cancer research and improving patient care,” said Ramon E. Parsons, MD, PhD, Director of the Mount Sinai Tisch Cancer Center and Dean for Cancer Research at the Icahn School of Medicine at Mount Sinai. “The breadth of research being presented by Mount Sinai investigators reflects our commitment to translating scientific discovery into more effective, personalized treatments and better outcomes for patients with cancer.”
Among the highlights is a late-breaking oral presentation by John Mascarenhas, MD, Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai and Director of the Center of Excellence for Blood Cancer and Myeloid Disorders at Mount Sinai Tisch Cancer Center, who will present findings from the phase 3 SENTRY trial evaluating selinexor plus ruxolitinib in patients with JAK inhibitor-naïve myelofibrosis. The study will be presented during the Hematologic Malignancies oral abstract session on June 2.
Additional Mount Sinai research being presented at ASCO includes studies examining novel immunotherapies and antibody-drug conjugates in lung cancer, circulating tumor DNA and biomarker-driven approaches in urothelial cancer, treatment strategies for relapsed/refractory multiple myeloma, and outcomes research focused on head and neck cancer and gynecologic malignancies.
Selected Mount Sinai Contributions at ASCO 2026
Session: Oral Abstract Session—Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Title: Selinexor plus ruxolitinib in JAK inhibitor-naïve myelofibrosis: Phase 3 SENTRY trial
https://www.asco.org/abstracts-presentations/259073
John Mascarenhas, MD
Abstract # LBA6500
Tuesday, June 2 , 9:45 am CDT
Room S100A
Session: Rapid Oral Abstract Session
Title: Efficacy and safety of HLX43 (anti–PD-L1 ADC) in patients with advanced non-small cell lung cancer
https://www.asco.org/abstracts-presentations/261382
Fred R. Hirsch, MD, PhD (senior author)
Abstract # 8512
Saturday, May 30 , 1:15 pm CDT
Hall D2
Posters:
CXCL9:SPP1 ratio: Macrophage polarization and outcomes with pembrolizumab or enfortumab vedotin plus pembrolizumab in metastatic urothelial cancer
https://www.asco.org/abstracts-presentations/262643
Saad Atiq, MD, and Matthew Galsky, MD
Abstract #: 542398
Poster Bd #: 52
Sunday, May 31
9 am-noon CDT
Hall A - Posters and Exhibits
Trends in end-of-life immunotherapy use in metastatic head and neck squamous cell carcinoma: A National Cancer Database analysis
https://www.asco.org/abstracts-presentations/263356
Session: Head and Neck Cancer
Ronit Sethi; Maaike van Gerwen, MD, PhD; Scott Roof, MD
Abstract #: 6035
Saturday, May 30
1:30 pm-4:30 pm CDT
Hall A - Posters and Exhibits
Overall survival of patients with mucosal melanoma in the US before and after the advent of PD-1 based immune checkpoint inhibitor treatment
https://www.asco.org/abstracts-presentations/261730
Olivia First and Maaike van Gerwen, MD, PhD
Abstract #: 9546
Poster Bd #: 262
Sunday, May 31
9 am-noon CDT
Hall A - Posters and Exhibits
Comparative efficacy of belantamab mafodotin plus bortezomib and dexamethasone (BVd) vs standard of care in patients with relapsed/refractory multiple myeloma (RRMM)
https://www.asco.org/abstracts-presentations/267968
Joshua Richter, MD
Abstract #7568
Poster Bd #447
Monday, June 1
9 am – noon CDT
Hall A - Posters and Exhibits
Keratin 19 (KRT19) as a circulating biomarker to measure disease burden and guide treatment in urothelial cancer
https://www.asco.org/abstracts-presentations/260701
Eric Miller, MD
Abstract #4591
Poster Bd #70
Sunday, May 31
9 am-noon CDT
Hall A - Posters and Exhibits
Quantitative pre-cystectomy ctDNA levels for identification of ctDNA-positive patients with surgically curable loco-regional disease versus those with occult micrometastatic progression
https://www.asco.org/abstracts-presentations/262647
Ruveyda Ayasun, MD, PhD, and Matthew Galsky, MD
Abstract #4577
Poster Bd #56
Sunday, May 31
9am – noon CDT
Hall A - Posters and Exhibits
A phase 1b, two-arm study of tolododekin alfa (ANK-101) in combination with an anti-PD-1/PD-L1 antibody in participants with advanced non-small cell lung cancer (NSCLC)
https://www.asco.org/abstracts-presentations/266782
Thomas Marron, MD, PhD
Abstract #TPS2678
Poster Bd #461b
Saturday, May 30
1:30pm – 4:30pm CDT
Hall A - Posters and Exhibits
CheckMate-901: Association of tumor and peripheral biomarker profiles with durable disease control in metastatic urothelial carcinoma treated with nivolumab plus ipilimumab
https://www.asco.org/abstracts-presentations/262606
Matthew Galsky, MD
Abstract #4525
Poster Bd #4
Sunday, May 31
9am – noon CDT
Hall A - Posters and Exhibits
TROPION-Urothelial03: A phase 2/3 study of datopotamab deruxtecan (Dato-DXd) + platinum chemotherapy (CT) vs gemcitabine + platinum CT in participants with locally advanced or metastatic urothelial carcinoma (la/mUC) with progression on or after enfortumab vedotin (EV) + pembrolizumab
https://www.asco.org/abstracts-presentations/266904
Matthew Galsky, MD
Abstract #TPS4642
Poster Bd #114b
Sunday, May 31
9am – noon CDT
Hall A - Posters and Exhibits
Treatment patterns and outcomes in pacritinib-treated patients with MF and higher platelet count: MY-PAC study
https://www.asco.org/abstracts-presentations/267846
Naveen Pemmaraju, MD, and Douglas Trembly, MD
Abstract #6575
Poster Bd #368
Monday, June 1
9am – noon CDT
Hall A - Posters and Exhibits
Updated protocol: IMPROVEMF, a phase 1b trial of imetelstat (IME)+ ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1/2 or high-risk (HR) myelofibrosis (MF)
https://www.asco.org/abstracts-presentations/266659
John Mascarenhas, MD
Abstract #TPS6604
Poster Bd #394b
Monday, June 1
9am – noon CDT
Hall A - Posters and Exhibits
For more information about the ASCO Annual Meeting, visit ASCO Annual Meeting .
About the Mount Sinai Tisch Cancer Center
The Mount Sinai Tisch Cancer Center is a vital component of the Icahn School of Medicine at Mount Sinai and the Mount Sinai Health System, which encompasses seven hospitals and more than 400 physician practices across the New York City metropolitan area. The mission of the Mount Sinai Tisch Cancer Center—a National Cancer Institute-designated Comprehensive Cancer Center—is to advance basic, clinical, and population health cancer research in order to prevent cancer in healthy individuals and improve the lives of people with cancer and their families in its communities. Its research programs are focused on the needs of its catchment area population and include extensive research in liver, prostate, breast, bladder, and lung cancers; myeloid preleukemia and leukemia; and multiple myeloma. The Mount Sinai Tisch Cancer Center features multidisciplinary, innovative cancer care. It has a robust portfolio of cancer clinical trials and an Early-Phase Trial Unit focused on novel therapies for optimal patient outcomes. Construction of the state-of-the-art Mount Sinai Tisch Cancer Hospital began in spring 2026 and is expected to be completed in the coming years, further expanding Mount Sinai’s capacity to deliver innovative, patient-centered cancer care.
* Mount Sinai Health System hospitals: The Mount Sinai Hospital; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.